Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
---|
11/23/2006 | US20060264492 methyl [5(6)-(4-alanylaminophenylthio)-1H-benzimidazol-2yl]carbamate; for treating neovascularization, solid tumors, macular degeneration, diabetic retinopathy, rheumatoid arthritis, psoriasis, and atherosclerosis |
11/23/2006 | US20060264479 Nicotinamide Derivatives Useful as p38 Inhibitors |
11/23/2006 | US20060264452 Analgesics; immunomodulators and for treatment of drug dependence; for example, 5'-Bromo-17-(cyclopropylmethyl)-6,7-didehydro-3,14-dihydroxy-4,5 alpha -epoxypyrido[2',3':6,7]morphinan |
11/23/2006 | US20060264436 Method of Treating a Psychotic Disorder |
11/23/2006 | US20060264434 Chemokine receptor binding heterocyclic compounds |
11/23/2006 | US20060264432 Adenosine A1, A2a, and A2b receptor ligands; coupling the 2-mercapto-3,5-dicyano-4-aryl-6-aminopyridine to a substituted alkyl or alkenyl compound; antiischemic agents; cardiovascular disorders |
11/23/2006 | US20060264417 N-(3-tetrahydrobenzodiazepinonyl)succamides: 2R,3S)N1-[1,3,4,5-tetrahydro-1-(3-phenoxybenzyl)-2-oxo-5-(phenyl)-2H-1,5-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(propyl)-butanediamide; inhibit production of A beta -peptide, preventing neurological amyloid deposits; Alzheimer's disease |
11/23/2006 | US20060264397 Compositions and methods for targeting cancer cells |
11/23/2006 | US20060264390 Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
11/23/2006 | US20060264389 Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
11/23/2006 | US20060264378 Cxcr4 antagonist and use thereof |
11/23/2006 | US20060263881 Methods of expanding and selecting disease associated T-Cells |
11/23/2006 | US20060263854 Immunodiagnostic assays using reducing agents |
11/23/2006 | US20060263852 Asp2 |
11/23/2006 | US20060263849 The analogs are resistant to diaminopeptidase IV degradation and bind zinc; are active over an extended time in vivo |
11/23/2006 | US20060263430 instrument for inducing cytokine and method of inducing cytokine |
11/23/2006 | US20060263392 Method for treating neovascularization |
11/23/2006 | US20060263388 Injectable or oral administration of a drug with an active ingredient of an extract from inflamed cutaneous tissue of rabbits inoculated with vaccinia virus; side effect reduction |
11/23/2006 | DE60202452C5 Pyridazinonaldose reductase inhibitoren Reductase inhibitors Pyridazinonaldose |
11/23/2006 | CA2609102A1 Int6 protein involved in hypoxia stress induction and use thereof |
11/23/2006 | CA2608957A1 Pyrrolidine derivative or salt thereof |
11/23/2006 | CA2607472A1 Antipyretic agents against vr1-antagonist-induced increases in body temperature |
11/22/2006 | EP1724349A1 TIE Ligand Homologues |
11/22/2006 | EP1724339A1 Gene regulation therapy involving ferritin |
11/22/2006 | EP1724283A2 Corticotropin releasing factor receptor 2 agonists |
11/22/2006 | EP1724279A2 5-Beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia. |
11/22/2006 | EP1724278A1 Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs |
11/22/2006 | EP1724271A1 Preventive and/or therapeutic agent for neutrophilic inflammation disease |
11/22/2006 | EP1724270A2 Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents |
11/22/2006 | EP1724267A1 Pyrimidine derivative |
11/22/2006 | EP1724264A1 Nitriles and medicinal compositions containing the same as the active ingredient |
11/22/2006 | EP1724263A1 Basic amine compound and use thereof |
11/22/2006 | EP1724262A1 1-(2h)-isoquinolone derivative |
11/22/2006 | EP1724258A1 Heteroarylphenylurea derivative |
11/22/2006 | EP1724257A1 Medicinal composition for prevention or treatment of overactive bladder accompanying nervous disorder |
11/22/2006 | EP1723970A1 Medicinal composition containing cxcr3 inhibitor |
11/22/2006 | EP1723959A1 Composition comprising platelet-rich plasma |
11/22/2006 | EP1723953A1 Nutritional supplements |
11/22/2006 | EP1723950A2 Method of treating dopaminergic gaba-nergic disorders |
11/22/2006 | EP1723854A1 Beverage or drug containing bamboo extract as main ingredient |
11/22/2006 | EP1722766A2 Management of ophthalmologic disorders, including macular degeneration |
11/22/2006 | EP1551860B1 Glucocorticoid receptor ligands for the treatment of metabolic disorders |
11/22/2006 | EP1534265B1 Combination of an aromatase inhibitor with a bisphosphonate |
11/22/2006 | EP1483265B1 Purine derivatives as kinase inhibitors |
11/22/2006 | EP1480620B1 (ester)-lysolecithins in liposomes |
11/22/2006 | EP1467982B1 Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them, and uses thereof |
11/22/2006 | EP1461034B1 Substituted imidazolidines, method for the production thereof, use thereof as a drug or for diagnosis, and drug containing substituted imidazolidines |
11/22/2006 | EP1458683B1 Heteroaryl-substituted aminocyclohexane derivatives |
11/22/2006 | EP1438055A4 D-tagatose as an anti-biofilm agent |
11/22/2006 | EP1438049B1 Substituted 4-phenyl-4-(1h-imidazol-2-yl)-piperidine derivatives for reducing ischaemic damage |
11/22/2006 | EP1427717B1 Bioprecursors for percutaneous application |
11/22/2006 | EP1423131B1 Calcium trifluoroacetate with cytotoxic activity |
11/22/2006 | EP1407261A4 In vivo bioreactors |
11/22/2006 | EP1401413B1 Use of tyrosine kinase inhibitions for treating allergic diseases |
11/22/2006 | EP1399156B1 Alkylidene pirazolidinedione derivatives and their use for treating diabetes and obesity |
11/22/2006 | EP1390360B1 Crystalline form of omeprazole |
11/22/2006 | EP1370575B1 Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus |
11/22/2006 | EP1351933B1 Il-8 receptor antagonists |
11/22/2006 | EP1317450B1 Pyrazole compounds useful as protein kinase inhibitors |
11/22/2006 | EP1312364B1 Gatifloxacin as cytokine production inhibitor |
11/22/2006 | EP1301487B1 Viral polymerase inhibitors |
11/22/2006 | EP1301475B1 Aryl sulfonamides as serotonin antagonist for the treatment of obesity |
11/22/2006 | EP1294757B1 Glucagon-like peptide-1 analogs |
11/22/2006 | EP1268435B1 4,5-dihydro-1h-pyrazole derivatives having cb 1-antagonistic activity |
11/22/2006 | EP1268412B1 Sulphonamido-substituted bridged bicycloalkyl derivatives |
11/22/2006 | EP1244651B1 Diamidine compounds as dna minor groove binders |
11/22/2006 | EP1220682B1 Stabilized liquid polypeptide-containing pharmaceutical compositions |
11/22/2006 | EP1146899B1 Methods of using neurotrophin 3 (nt-3) for the treatment of gastrointestinal hypomotility disorders |
11/22/2006 | EP1120114B1 Compositions and methods for treating conditions responsive to estrogen |
11/22/2006 | EP1078054B1 Monomeric mp52/gdf-5 with bone morphogenetic activity and medicinal agent containing the same for preventing and treating diseases of cartilage and bone |
11/22/2006 | EP1066247B1 Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
11/22/2006 | EP1051176B1 SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS |
11/22/2006 | EP1037603B1 Membrane virus host range mutations and their uses as vaccine substrates |
11/22/2006 | EP0970104B1 Steroid sulfamates, method for the production and use thereof |
11/22/2006 | EP0942925B1 Inhibitors of interleukin-1 beta converting enzyme |
11/22/2006 | EP0939821B1 G-beta-gamma regulated phosphatidylinositol-3' kinase |
11/22/2006 | CN1867560A 4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors |
11/22/2006 | CN1867552A Probe for disease with amyloid deposit, amyloid-staining agent, remedy and preventive for disease with amyloid deposit and diagnostic probe and staining agent for neurofibril change |
11/22/2006 | CN1867547A Compounds having crth2 antagonist activity |
11/22/2006 | CN1867339A Novel use of cannabinoid receptor agonist |
11/22/2006 | CN1864741A 'Huo Xiang Zheng Qi' essence powder for poultry and livestock, its preparation process and application method |
11/22/2006 | CN1864696A New formulation |
11/22/2006 | CN1864693A A glycerin and fructose injection and preparation method thereof |
11/22/2006 | CN1864677A An anti-thrombus anti-restenosis composite medicine coated on eluting stent |
11/22/2006 | CN1864543A A nutrition food for postponing human senescence |
11/22/2006 | CN1864534A Pure natural health noodle with astragalus root and asiabell root |
11/22/2006 | CN1285594C Oxytocin agonists |
11/22/2006 | CN1285591C Dimeric compounds and their use as anti-viral agents |
11/22/2006 | CN1285588C Farnesyl protein transferase inhibitors |
11/22/2006 | CN1285578C Substituted benzoic acid amides and use for inhibition of angiogenesis thereof |
11/21/2006 | US7138543 Thiolalkyl benzoic acid derivatives |
11/21/2006 | US7138533 acetylcholinesterase inhibitory action and an alpha 1 antagonistic action |
11/21/2006 | US7138531 Preparation and use of carbohydrate-based bicyclic ring structures with antimicrobial and cytostatic activity |
11/21/2006 | US7138530 for inhibiting the enzyme C1s, a protease in the classical pathway of the complement system; and the use of this inhibition to treat or ameliorate acute or chronic disorders in mammals |
11/21/2006 | US7138524 Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
11/21/2006 | US7138492 Promoting survival of substantia nigra neuronal cells by contacting with a trophic amount of a ptc therapeutic; mimics hedgehog-mediated patched signal transduction; treating or preventing Parkinson's Disease |
11/21/2006 | US7138432 Arylsulfonamido-substituted hydroxamic acid derivatives |
11/21/2006 | US7138430 Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use |
11/21/2006 | US7138428 Compounds isolated from gamboge resin having activity in inhibiting the growth of tumor/cancer cells and pharmaceutical compositions comprising the same |
11/21/2006 | US7138427 Cognition activators |